269 related articles for article (PubMed ID: 33155281)
1. Immunotherapeutic strategies in breast cancer: A clinical update.
Zhang JQ; Plitas G
J Surg Oncol; 2021 Mar; 123(3):710-717. PubMed ID: 33155281
[TBL] [Abstract][Full Text] [Related]
2. Prognostic and therapeutic role of tumor-infiltrating lymphocyte subtypes in breast cancer.
Nelson MA; Ngamcherdtrakul W; Luoh SW; Yantasee W
Cancer Metastasis Rev; 2021 Jun; 40(2):519-536. PubMed ID: 33963482
[TBL] [Abstract][Full Text] [Related]
3. Combined Radiation Therapy and Immune Checkpoint Blockade Therapy for Breast Cancer.
Hu ZI; Ho AY; McArthur HL
Int J Radiat Oncol Biol Phys; 2017 Sep; 99(1):153-164. PubMed ID: 28816141
[TBL] [Abstract][Full Text] [Related]
4. Current status of PD-1/PD-L1 blockade immunotherapy in breast cancer.
Noguchi E; Shien T; Iwata H
Jpn J Clin Oncol; 2021 Mar; 51(3):321-332. PubMed ID: 33324990
[TBL] [Abstract][Full Text] [Related]
5. Tumour-infiltrating lymphocytes and the emerging role of immunotherapy in breast cancer.
Luen SJ; Savas P; Fox SB; Salgado R; Loi S
Pathology; 2017 Feb; 49(2):141-155. PubMed ID: 28049579
[TBL] [Abstract][Full Text] [Related]
6. Reconstituting Immune Surveillance in Breast Cancer: Molecular Pathophysiology and Current Immunotherapy Strategies.
Cilibrasi C; Papanastasopoulos P; Samuels M; Giamas G
Int J Mol Sci; 2021 Nov; 22(21):. PubMed ID: 34769447
[TBL] [Abstract][Full Text] [Related]
7. T-cell-based breast cancer immunotherapy.
Pilipow K; Darwich A; Losurdo A
Semin Cancer Biol; 2021 Jul; 72():90-101. PubMed ID: 32492452
[TBL] [Abstract][Full Text] [Related]
8. Advancing Immunotherapy in Metastatic Breast Cancer.
Mansour M; Teo ZL; Luen SJ; Loi S
Curr Treat Options Oncol; 2017 Jun; 18(6):35. PubMed ID: 28534250
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy for the treatment of breast cancer: checkpoint blockade, cancer vaccines, and future directions in combination immunotherapy.
McArthur HL; Page DB
Clin Adv Hematol Oncol; 2016 Nov; 14(11):922-933. PubMed ID: 27930644
[TBL] [Abstract][Full Text] [Related]
10. Integrating immunotherapy in the (neo)adjuvant setting of early breast cancer.
Chan JJ; Tan TJY; Dent RA
Curr Opin Oncol; 2020 Nov; 32(6):575-584. PubMed ID: 32852307
[TBL] [Abstract][Full Text] [Related]
11. Immune checkpoint inhibitors: review of the existing evidence and challenges in breast cancer.
Jalalvand M; Darbeheshti F; Rezaei N
Immunotherapy; 2021 May; 13(7):587-603. PubMed ID: 33775102
[TBL] [Abstract][Full Text] [Related]
12. Development of Tumor Markers for Breast Cancer Immunotherapy.
Fang Q; Shen G; Xie Q; Guan Y; Liu X; Ren D; Zhao F; Liu Z; Ma F; Zhao J
Curr Mol Med; 2024; 24(5):547-564. PubMed ID: 37157196
[TBL] [Abstract][Full Text] [Related]
13. Targeting Innate Immunity in Breast Cancer Therapy: A Narrative Review.
Ye Y; Xu C; Chen F; Liu Q; Cheng N
Front Immunol; 2021; 12():771201. PubMed ID: 34899721
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy for esophageal cancer: a 2019 update.
Schizas D; Charalampakis N; Kole C; Mylonas KS; Katsaros I; Zhao M; Ajani JA; Psyrri A; Karamouzis MV; Liakakos T
Immunotherapy; 2020 Feb; 12(3):203-218. PubMed ID: 32208794
[TBL] [Abstract][Full Text] [Related]
15. Pre-existing effector T-cell levels and augmented myeloid cell composition denote response to CDK4/6 inhibitor palbociclib and pembrolizumab in hormone receptor-positive metastatic breast cancer.
Egelston C; Guo W; Yost S; Lee JS; Rose D; Avalos C; Ye J; Frankel P; Schmolze D; Waisman J; Lee P; Yuan Y
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33757987
[TBL] [Abstract][Full Text] [Related]
16. [Immunoncology and tumor infiltrating lymphocytes-new strategies for therapy and diagnosis of breast cancer].
Denkert C
Pathologe; 2020 May; 41(3):248-253. PubMed ID: 32246201
[TBL] [Abstract][Full Text] [Related]
17. Antitumor immunity and advances in cancer immunotherapy.
Sugie T; Toi M
Breast Cancer; 2017 Jan; 24(1):1-2. PubMed ID: 27882505
[No Abstract] [Full Text] [Related]
18. Tumor-infiltrating lymphocytes and breast cancer: Beyond the prognostic and predictive utility.
Ravelli A; Roviello G; Cretella D; Cavazzoni A; Biondi A; Cappelletti MR; Zanotti L; Ferrero G; Ungari M; Zanconati F; Bottini A; Alfieri R; Petronini PG; Generali D
Tumour Biol; 2017 Apr; 39(4):1010428317695023. PubMed ID: 28378631
[TBL] [Abstract][Full Text] [Related]
19. [Immunotherapy opportunities in breast cancer].
Pusztai L; Ladányi A; Székely B; Dank M
Magy Onkol; 2016 Mar; 60(1):34-40. PubMed ID: 26934349
[TBL] [Abstract][Full Text] [Related]
20. Prospect of immunotherapy in neoadjuvant/adjuvant treatment for early breast cancer.
Miyashita M; Ishida T
Chin Clin Oncol; 2020 Jun; 9(3):28. PubMed ID: 32312056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
